Download Files:
Cevipabulin
$168 – $1,140
Products Details
Product Description
– Cevipabulin (TTI-237) is an oral, microtubule-active antitumor compound and inhibits the binding of [3H] vinblastine to tubulin, with an IC50 of 18-40 nM for cytotoxicity in human tumor cell line[1][2].
Web ID
– HY-14949
Storage Temperature
– -20°C, 3 years (Powder)
Shipping
– Blue Ice
Applications
– Cancer-programmed cell death
Molecular Formula
– C18H18ClF5N6O
References
– [1]Beyer CF, et al. TTI-237: a novel microtubule-active compound with in vivo antitumor activity. Cancer Res. 2008 Apr 1;68(7):2292-300.|[2]Beyer CF, et al. The microtubule-active antitumor compound TTI-237 has both paclitaxel-like and vincristine-like properties. Cancer Chemother Pharmacol. 2009 Sep;64(4):681-9.
CAS Number
– 849550-05-6
Molecular Weight
– 464.82
Compound Purity
– 98.0
SMILES
– C[C@@]([H])(C(F)(F)F)NC1=C(C2=C(F)C=C(OCCCNC)C=C2F)C(Cl)=NC3=NC=NN13
Clinical Information
– Phase 1
Research Area
– Cancer
Solubility
– DMSO : 16.67 mg/mL (ultrasonic)
Target
– Microtubule/Tubulin
Pathway
– Cell Cycle/DNA Damage;Cytoskeleton
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
